Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

Medicine & Life Sciences

• human GAA protein 100%
• Glycogen Storage Disease Type II 83%
• Late Onset Disorders 77%
• Multicenter Studies 50%
• Safety 33%
• Walk Test 10%
• Vital Capacity 9%
• Therapeutics 9%
• Glycogen 9%
• Population 6%
• Glucosidases 6%
• IGF Type 2 Receptor 6%
• Enzyme Replacement Therapy 5%
• Least-Squares Analysis 4%
• Neutralizing Antibodies 4%
• Standard of Care 4%
• Antibody Formation 4%
• Walking 3%
• Acids 3%
• Myocardial Infarction 3%
• Research Personnel 3%
• Health Care Outcome Assessment 2%
• Demography 2%
• Enzymes 2%